Entinostat/IL-2 Combination Active in Previously Untreated Renal Cell Carcinoma


More than one-third of patients with previously untreated renal cell carcinoma responded to the combination of high-dose interleukin-2 and an investigational histone deacetylase inhibitor entinostat.

Roberto Pili, MD

More than one-third of patients with previously untreated renal cell carcinoma (RCC) responded to the combination of high-dose interleukin-2 (IL-2) and an investigational histone deacetylase (HDAC) inhibitor entinostat, according to results of a phase I/II trial presented at the 2016 AACR Annual Meeting.

High-dose IL-2 and entinostat led to an overall response rate (ORR) of 37% in 47 patients. The study population had a median progression-free survival (PFS) of more than 1 year, increasing to more than 2 years in responding patients.

“Reduced levels of regulatory T cells (Tregs) following entinostat treatment may be associated with objective responses,” said Roberto Pili, MD, a professor of Medicine at Indiana University in Indianapolis. “These results suggest that the selective class I HDAC inhibitor entinostat may increase the anti-tumor effect of high-dose IL-2 by modulating immunosuppressive cells.”

High-dose IL-2 is a treatment option for selected patients with metastatic RCC, resulting in an ORR of 15% in 255 patients treated in 7 clinical trials (J Clin Oncol. 1995;13:688-696). More recently, a prospective study involving 120 patients showed an objective response rate of 25% and median PFS of 4.2 months with high-dose IL-2 (Clin Cancer Res. 2015;21:561-568).

High-dose IL-2 and entinostat exhibited synergistic antitumor activity in a murine model of RCC (Clin Cancer Res. 2007;13 (15 Pt 1):4538-4546). Entinostat inhibits the suppressive function of Tregs (PLoS One. 2012;7:e30815), and low numbers of Tregs have been associated with better outcomes in patients receiving high dose IL-2.

“The inhibitor effect of entinostat on Tregs may increase the response rate and progression-free survival in patients receiving high-dose IL-2,” said Pili.

To evaluate the safety and estimate the efficacy high-dose IL-2 plus entinostat, investigators enrolled patients with previously untreated RCC into the phase I/II trial. A response rate of 20% or less was considered unsuccessful, while a response rate of 40% or greater was considered sufficiently active to warrant further investigation.

The 47 patients enrolled in the trial had a median age of 58, and all had undergone nephrectomy. Slightly more than half (53%) the patients met Memorial Sloan Kettering criteria for favorable risk, and the remaining patients had intermediate-risk disease status. Pili said 36 patients had lung metastases, and 26 had lymph node involvement.

Treatment consisted of entinostat at a dose of 3 mg or 5 mg every 14 days (beginning 14 days before the start of IL-2) and IL-2 at a dose of 600,000 u/kg every 8 hours for a maximum of 14 doses. One treatment cycle lasted 85 days.

Among 41 evaluable patients, 15 (37%) had objective responses, including three complete responses. An additional 18 patients (44%) had stable disease. Median PFS was 13.8 months. Responding patients had a median PFS of 28.5 months versus 5.7 months for patients who did not achieve an objective response (P = 0.0015). The cohort had a median overall survival of 65 months, and an estimated 3-year survival of 81%.

Pre- and post-treatment biopsies suggested an association between decreased Tregs and both objective response and durable stable disease. Specifically, responding patients had lower levels of Tregs on day 1 of a treatment cycle (start of high-dose IL-2). Additionally, responding patients had higher levels of antigen-presenting cells from day 7 to day 1 of cycle 1 and increasing levels from day -14 to day 1 of cycle 1.

The combination was found to be safe; however, it was associated with high rates of grade 3 hypophosphatemia and lymphopenia.

Grade 3/4 toxicities included hypophosphatemia (16.4%), lymphopenia (15.1%) hypocalcemia (7.2%), thrombocytopenia (6.4%), and hyponatremia (5.3%).

Pili R, Quinn DI, Hammers HJ, et al. Results from a phase I/II study with the HDAC inhibitor entinostat in combination with high-dose interleukin 2 in renal cell carcinoma patients (CTEP#7870). Presented at: AACR 2016 Annual Meeting; New Orleans, Louisiana, April 16-20, 2016. Abstract CT015.


View more from the 2016 AACR Annual Meeting

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Brian I. Rini, MD, FASCO
Sheldon M. Feldman, MD
Rita Mukhtar, MD
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Marc Machaalani, MD